Finding a doctor for insulin resistance: what to look for

The right doctor for insulin resistance does three things your last physical probably skipped: measures fasting insulin alongside HbA1c instead of glucose alone, treats insulin resistance as a whole-system driver rather than a pre-diabetes waiting room, and re-tests on a schedule short enough to steer treatment. Most primary care does none of the three, not from negligence but from design. This guide tells you what to look for, what to ask, and what the treatment actually looks like when someone takes it seriously.

Why this condition hides in plain sight

Insulin resistance means your tissues respond sluggishly to insulin, so your pancreas compensates by producing more of it. For years, sometimes decades, the compensation works: glucose stays normal, the basic panel stays clean, and the clinician sees nothing to act on. Meanwhile the elevated insulin itself is doing damage through other doors. It drives sodium retention and rising blood pressure. It pushes the liver to export more triglycerides and to store fat. It worsens PCOS in women and contributes to erectile dysfunction in men. It makes weight loss structurally harder, which gets misread as a character problem.

The Centers for Disease Control and Prevention frames prediabetes as a reversible stage, which is true and useful, but the framing also reinforces the wrong default: wait until glucose crosses a line, then act. By the time fasting glucose or HbA1c moves, the insulin compensation has usually been running for years. The right question is not whether you are prediabetic yet. It is what your insulin is doing today.

The labs that find it

This is where the choice of clinician matters more than the choice of pharmacy. A proper insulin resistance workup is short and inexpensive, and almost nobody running a fifteen-minute visit orders it:

In our Biomarker Audit, this whole panel repeats every 90 days, because insulin resistance is a moving target that responds to intervention on exactly that timescale. A single draw tells you where you are; a trend tells you whether the plan is working.

What the treatment actually looks like

We will be direct about the ladder, because the industry over-sells the top rung and under-sells the rest.

Nutrition structure comes first. Not a diet brand; a structure that lowers insulin demand: adequate protein, controlled carbohydrate timing, and a calorie level matched to your actual metabolism. This is also where the honest money conversation lives. Medications amplify a plan; they do not replace one.

Resistance training is the insulin-sensitivity drug with no side effects. Muscle is the largest glucose sink in the body, and two or three sessions a week measurably improve insulin sensitivity. We pair this with every weight-loss protocol, because muscle preservation is the difference between weight loss that heals and weight loss that weakens.

Sleep and stress repair. Fragmented sleep raises insulin resistance by itself. A clinician who never asks about your sleep is treating your labs with one hand tied.

Branded GLP-1 therapy when the labs justify it. For patients whose markers show real metabolic dysfunction, branded, FDA-approved GLP-1 medication is a genuine tool: it improves insulin sensitivity, drives clinically meaningful weight loss and lowers cardiovascular risk. We prescribe Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo, never compounded products. What we refuse to do is hand you a prescription instead of a diagnosis; the medication decision is made against the full panel, and it is re-tested quarterly like everything else.

What the ninety days actually look like

Because this page will be read by people deciding whether a different model of care is worth switching for, it is fair to describe the cadence concretely. Month one begins with the clinical intake and the first Biomarker Audit. The intake is where the history gets read properly: weight history, sleep, medications, family history, and the timeline of when the fatigue, the weight and the labs began to drift. The first panel establishes the baseline, and the first protocol conversation happens against it, with the mechanism named and the markers expected to move written down.

Month two is execution and adjustment. Nutrition structure is set, resistance training is scheduled at a frequency that will actually happen, sleep is addressed as a clinical variable rather than a lifestyle footnote, and if the panel justifies medication, it is introduced at the lowest effective dose with the monitoring plan attached. Questions in this month are answered quickly, because early adherence is where most plans actually fail, and a plan that cannot survive the first sixty days is not a plan.

Month three closes the loop. The audit repeats, and the comparison is made explicitly: fasting insulin, HbA1c, ApoB, hs-CRP and the hormone panel against their baselines. Where the numbers moved, the plan continues. Where they did not, the protocol is revised rather than defended, and the next audit holds the revision to the same standard. Four of these loops a year is what treating a mechanism rather than a symptom looks like in practice, and it is the reason the condition stops quietly worsening while nobody watches.

Why cash-pay membership care fits this condition

Here is the part worth saying plainly, because this page will be read by people who have spent years inside a high-deductible plan watching their money leave for care that never arrives. Insulin resistance is a management condition. It needs a full panel, an unhurried conversation about food and sleep and training, a written protocol, and a re-test every quarter. Fee-for-service medicine is paid per visit, per problem, per prescription, and it is structurally bad at exactly this shape of care. You leave with a glucose value and a follow-up in a year, and the compensation has run another twelve months.

Direct membership care inverts the incentive. In our model the membership is one flat $299 per month, and it covers the clinical relationship: the quarterly Biomarker Audit with the full metabolic, lipid, hormone and thyroid panels, the clinician who reads it and answers between visits, and the written protocol. The first charge at checkout is $598, which covers the first two months together: the clinical intake, the first comprehensive panel, and the second month of care while your protocol is built. From month three it is $299 per month, month to month, cancel anytime after the initial commitment.

The medicine is a separate charge, billed by the pharmacy at pharmacy cost with zero markup, no molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols, and labs run through the Beluga Health lab network. HSA and FSA funds can typically be applied to membership care; confirm eligibility with your plan administrator.

If you have been carrying a rising A1c, a stubborn midsection or labs that keep coming back borderline while being told everything is fine, start with the eligibility assessment or read the definitive guide to cardiometabolic optimization. The most likely outcome of one proper panel is a named mechanism and a plan aimed at it, which is the outcome your last five physicals have been postponing.

FAQ

What kind of doctor treats insulin resistance? Any physician can, but the ones who do it well practice with time and panels: a clinician who orders fasting insulin alongside HbA1c, reads lipids as a pattern rather than a flag, and re-tests quarterly. Endocrinologists handle severe cases; for the common early-to-moderate stage, a membership-based primary care relationship with full lab panels is the most practical fit.

Can insulin resistance be reversed? Largely yes, and the evidence is strong: weight loss of even 5 to 10 percent, resistance training and improved sleep measurably improve insulin sensitivity, and the CDC's own Diabetes Prevention Program literature documents reduced progression to type 2 diabetes. Reversal means normal insulin dynamics on re-tested labs, not just a normal glucose.

What labs show insulin resistance? Fasting insulin paired with HbA1c, the triglyceride to HDL ratio, ApoB, hs-CRP and liver enzymes. A normal fasting glucose with a fasting insulin three times ideal is the classic hidden pattern.

Is a GLP-1 appropriate for insulin resistance without diabetes? For selected patients, yes: branded GLP-1 medications improve insulin sensitivity and produce clinically meaningful weight loss in people without diabetes, and trial evidence supports cardiovascular benefit. It is a tool inside a metabolic plan, prescribed against labs and re-tested, never a substitute for the plan.

How often should insulin resistance be re-tested? Every 90 days while a plan is being executed. Insulin sensitivity, HbA1c, lipids and inflammation all respond on that timescale, and quarterly measurement is what converts a hope into a protocol.

Is this care eligible for HSA or FSA funds? Membership-based direct primary care is typically HSA and FSA eligible, though rules vary by plan; confirm with your administrator. For patients carrying a high deductible, paying directly for the care that actually prevents the deductible event is usually the better math.

Related guides

• Cardiometabolic optimization: the definitive guide
• ApoB vs LDL cholesterol: which test predicts risk
• Direct primary care at GoodLife Health
• Biomarker audits vs standard blood tests

References

1. CDC: Prevent Type 2 Diabetes (Prediabetes overview). 2024. www.cdc.gov/diabetes/prevention-type-2/prediabetes-prevention.html
2. American Diabetes Association: Standards of Care in Diabetes (Classification and Diagnosis). 2024. diabetesjournals.org/care/article/47/Supplement_1/S36/S153953